Agios

Agios is a biopharmaceutical company founded in 2008, specializing in cellular metabolism research. The firm focuses on developing novel therapeutics for rare genetic diseases and hematology. Its primary product, PYRUKYND (mitapivat), serves as a pyruvate kinase activator for hemolytic anemias. The company maintains a robust R&D pipeline, including AG-946 for myelodysplastic syndrome and AG-181 for phenylketonuria. Meet Agios's team to understand the scientific leadership driving these clinical advancements.

Operating with 500-1,000 employees, Agios maintains a research-driven approach to drug discovery. The company leverages small molecule technology to address complex metabolic pathways. Its operational footprint is centered in Cambridge, Massachusetts, where it conducts extensive clinical trials and preclinical studies. The organization's commitment to patient support programs and translational science underscores its position within the competitive biopharmaceutical landscape, where it operates alongside peers like Alnylam Pharmaceuticals and Blueprint Medicines.

Agios is a publicly traded entity under the ticker NASDAQ: AGIO. The company reported annual revenue of $98.3M, reflecting its ongoing investment in therapeutic development and clinical pipeline expansion. Explore financial highlights to review detailed metrics regarding the company's fiscal performance and funding history, including its 2013 stock issuance. As a member of the Russell 3000 index, Agios continues to prioritize the translation of cellular metabolism science into viable clinical treatments for patients suffering from rare blood disorders and other metabolic conditions.